News Otsuka's Voyxact faces rival as FDA okays Vera IgAN drug Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgAN that will compete with Otsuka's recently-launched Voyxact.
News Despite US policy changes, drug prices stay stubbornly high US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.